10-K Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001493152-21-006807`
Period End Date	20201231
Filing Date	20210325
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	pcsa-20201231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 84 Income Statement 22 Cash Flow Statement 83 Stockholders Equity 29

Balance Sheet 84 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	30.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	30.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$691.54K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$15.42M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.49M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.19M	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$154.73K	USD	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.19M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.49M	shares	Point-in-time
Due from tax agencies	`DueFromTaxAgencies`	$77.02K	USD	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	-	shares	Point-in-time
Due from tax agencies	`DueFromTaxAgencies`	-	USD	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	28,971.00	shares	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$315.61K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$554.71K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$16.20M	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$1.01M	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$28.58K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$20.14K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$8.93K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$484.00	USD	Point-in-time
Operating lease right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$219.07K	USD	Point-in-time
Operating lease right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$158.56K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$8.85M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$9.64M	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$9.01M	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$9.87M	USD	Point-in-time
Total Assets	`Assets`	$25.21M	USD	Point-in-time
Total Assets	`Assets`	$10.88M	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	-	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$802.50K	USD	Point-in-time
Note payable - Paycheck Protection Program, current portion	`NotesPayableCurrent`	-	USD	Point-in-time
Note payable - Paycheck Protection Program, current portion	`NotesPayableCurrent`	$117.57K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$87.20K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$77.99K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$950.00	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$21.90K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$320.69K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$75.61K	USD	Point-in-time
Due to licensor	`DueToLicensor`	-	USD	Point-in-time
Due to licensor	`DueToLicensor`	$400.00K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$69.86K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$316.00	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$224.68K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$213.24K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$1.19M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$1.22M	USD	Point-in-time
Note payable - Paycheck Protection Program	`NotesPayable`	$44.88K	USD	Point-in-time
Note payable - Paycheck Protection Program	`NotesPayable`	-	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$78.46K	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$147.39K	USD	Point-in-time
Non-current due to licensor	`NoncurrentDueToLicensor`	-	USD	Point-in-time
Non-current due to licensor	`NoncurrentDueToLicensor`	$400.00K	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$1.53M	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$530.61K	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.27M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.87M	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.0001, 30,000,000 and 100,000,000 shares authorized at December 31, 2020 and 2019, 14,187,984 and 5,486,595 issued and outstanding at December 31, 2020 and 2019, respectively	`CommonStockValue`	$1.42K	USD	Point-in-time
Common stock, par value $0.0001, 30,000,000 and 100,000,000 shares authorized at December 31, 2020 and 2019, 14,187,984 and 5,486,595 issued and outstanding at December 31, 2020 and 2019, respectively	`CommonStockValue`	$549.00	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$48.33M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$18.99M	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	$3.00	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-25.40M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.98M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.01M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$22.94M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.70M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$25.21M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$10.88M	USD	Point-in-time

Income Statement 22 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$2.32M	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	$3.17M	USD	Annual
Acquisition of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$8.70M	USD	Annual
Acquisition of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	-	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.26M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.61M	USD	Annual
Operating Loss	`OperatingIncomeLoss`	$-3.94M	USD	Annual
Operating Loss	`OperatingIncomeLoss`	$-15.14M	USD	Annual
Interest expense	`InterestExpense`	$36.66K	USD	Annual
Interest expense	`InterestExpense`	$281.12K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.17K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$11.55K	USD	Annual
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-15.41M	USD	Annual
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.96M	USD	Annual
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-1.00M	USD	Annual
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-602.72K	USD	Annual
Net Loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net Loss	`NetIncomeLoss`	$-14.41M	USD	Annual
Net Loss Per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.70	USD	Annual
Net Loss Per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-2.54	USD	Annual
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	7.50M	shares	Annual
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.53M	shares	Annual

Cash Flow Statement 83 line items

Line Item	Tag	Value	Unit	Period
Net Loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net Loss	`NetIncomeLoss`	$-14.41M	USD	Annual
Depreciation	`Depreciation`	$8.45K	USD	Annual
Depreciation	`Depreciation`	$8.45K	USD	Annual
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	$78.29K	USD	Annual
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	$74.12K	USD	Annual
Non-cash acquisition of in-process research and development	`NoncashAcquisitionOfInprocessResearchAndDevelopment`	$8.60M	USD	Annual
Non-cash acquisition of in-process research and development	`NoncashAcquisitionOfInprocessResearchAndDevelopment`	-	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$1.78K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$199.90K	USD	Annual
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$795.33K	USD	Annual
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$795.33K	USD	Annual
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	$-1.00M	USD	Annual
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	$-602.72K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$2.73M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$510.48K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$239.10K	USD	Annual
Conversion of senior convertible debt, principal amount	`ConversionOfSeniorConvertibleDebtValue`	$230.00K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$57.77K	USD	Annual
Conversion of senior convertible debt, principal amount	`ConversionOfSeniorConvertibleDebtValue`	$805.00K	USD	Annual
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$77.49K	USD	Annual
Accrued interest	`InterestPayableCurrentAndNoncurrent`	$84.51K	USD	Point-in-time
Accrued interest	`InterestPayableCurrentAndNoncurrent`	$28.93K	USD	Point-in-time
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$77.78K	USD	Annual
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	247,088.00	shares	Annual
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	18,107.00	shares	Annual
Accrued interest, including amounts converted into common stock	`IncreaseDecreaseInInterestPayableNet`	$81.89K	USD	Annual
Accrued interest, including amounts converted into common stock	`IncreaseDecreaseInInterestPayableNet`	$30.49K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-216.49K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$245.08K	USD	Annual
Due (from) to related parties	`IncreaseDecreaseInDueFromRelatedParties`	$85.19K	USD	Annual
Due (from) to related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-21.90K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$77.02K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	-	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$119.94K	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$11.44K	USD	Annual
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.14M	USD	Annual
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.75M	USD	Annual
Proceeds from issuance of senior convertible notes	`ProceedsFromConvertibleDebt`	$805.00K	USD	Annual
Proceeds from issuance of senior convertible notes	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	-	USD	Annual
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	$900.00K	USD	Annual
Transaction costs incurred on senior convertible notes	`PaymentsOfDebtIssuanceCosts`	$4.28K	USD	Annual
Transaction costs incurred on senior convertible notes	`PaymentsOfDebtIssuanceCosts`	-	USD	Annual
Borrowings on line of credit from related party	`BorrowingsOnLineOfCreditPayableFromRelatedParty`	-	USD	Annual
Borrowings on line of credit from related party	`BorrowingsOnLineOfCreditPayableFromRelatedParty`	$700.00K	USD	Annual
Proceeds from our Paycheck Protection Program note payable	`ProceedsFromNotesPayable`	-	USD	Annual
Proceeds from our Paycheck Protection Program note payable	`ProceedsFromNotesPayable`	$162.46K	USD	Annual
Net proceeds from common stock offering	`ProceedsFromIssuanceOfCommonStock`	$17.10M	USD	Annual
Net proceeds from common stock offering	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Shares withheld to pay taxes on stock based compensation	`SharesWithheldToPayIncomeTaxOnStockbasedCompensation`	$95.21K	USD	Annual
Shares withheld to pay taxes on stock based compensation	`SharesWithheldToPayIncomeTaxOnStockbasedCompensation`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.70M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$17.87M	USD	Annual
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.05M	USD	Annual
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$14.72M	USD	Annual
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$15.42M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$15.42M	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	-	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	-	USD	Annual
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$293.20K	USD	Annual
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$17.77K	USD	Annual
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	-	USD	Annual
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	$-9.96K	USD	Annual
Operating lease liability	`OperatingLeaseLiabilities`	$17.77K	USD	Annual
Operating lease liability	`OperatingLeaseLiabilities`	$303.16K	USD	Annual
Net	`NonCashleaseLiabilityNet`	-	USD	Annual
Net	`NonCashleaseLiabilityNet`	-	USD	Annual
Conversion of $230,000 of Senior Convertible Debt and related accrued interest of $28,930 into 18,107 shares of common stock and warrants to purchase common stock	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$230.00K	USD	Annual
Conversion of $805,000 of Senior Convertible Debt and related accrued interest of $84,513 into 247,088 shares of common stock	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStock`	-	USD	Annual
Conversion of $805,000 of Senior Convertible Debt and related accrued interest of $84,513 into 247,088 shares of common stock	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStock`	$805.00K	USD	Annual
Conversion of $700,000 of Line of Credit Payable with related party and related accrued interest of $18,333 into 199,537 shares of common stock	`ConversionlineOfCreditPayableWithRelatedPartyAndRelatedAccruedInterestOfcommonStock`	$700.00K	USD	Annual
Conversion of $700,000 of Line of Credit Payable with related party and related accrued interest of $18,333 into 199,537 shares of common stock	`ConversionlineOfCreditPayableWithRelatedPartyAndRelatedAccruedInterestOfcommonStock`	-	USD	Annual
Issuance of 1,185,458 shares of common stock due to triggering the full-ratchet anti-dilution provision of common stock sold in our 2018 Private Placement Transactions	`IssuanceOfCommonStockDueToTriggeringFullRatchetAntiDilution`	-	USD	Annual
Issuance of 1,185,458 shares of common stock due to triggering the full-ratchet anti-dilution provision of common stock sold in our 2018 Private Placement Transactions	`IssuanceOfCommonStockDueToTriggeringFullRatchetAntiDilution`	$119.00	USD	Annual
Common stock and stock purchase warrants (forfeited)/issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	-	USD	Annual
Common stock and stock purchase warrants (forfeited)/issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	$-900.00K	USD	Annual

Stockholders Equity 29 line items

Line Item	Tag	Value	Unit	Period
Shares issued in connection with our 2020 offering, net of transaction costs	`PaymentsOfStockIssuanceCosts`	$2.10M	USD	Annual
Conversion of 8% senior convertible notes into shares of common stock	`DebtInstrumentInterestRateStatedPercentage`	0.08	pure	Point-in-time
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time
Balance	`StockholdersEquity`	$22.94M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Conversion of Senior convertible debt for common stock and stock purchase warrants	`StockIssuedDuringPeriodValueConversionOfUnits`	-	USD	Annual
Conversion of Senior convertible debt for common stock and stock purchase warrants	`StockIssuedDuringPeriodValueConversionOfUnits`	$258.93K	USD	Annual
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	-	USD	Annual
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$900.00K	USD	Annual
Pledged shares of common stock forfeited upon revised research funding commitment	`PledgeSharesOfCommonStockForfeitedUponRevisedResearchFundingCommitment`	-	USD	Annual
Pledged shares of common stock forfeited upon revised research funding commitment	`PledgeSharesOfCommonStockForfeitedUponRevisedResearchFundingCommitment`	-	USD	Annual
Deemed stock dividend due to full ratchet anti-dilution adjustment	`StockDividendtobeIssuedduetoFullRatchetAntidilutionAdjustment`	-	USD	Annual
Deemed stock dividend due to full ratchet anti-dilution adjustment	`StockDividendtobeIssuedduetoFullRatchetAntidilutionAdjustment`	-	USD	Annual
Shares issued in connection with our 2020 offering, net of transaction costs of $2,099,363	`StockIssuedDuringPeriodinConnectionwithOfferingnetTransactionCosts`	$17.10M	USD	Annual
Shares issued in connection with license agreements	`StockIssuedDuringPeriodValueOther`	$7.80M	USD	Annual
Shares issued due to full-ratchet anti-dilution adjustment	`StockIssuedvalueDueToFullratchetAntidilutionAdjustment`	-	USD	Annual
Conversion of LOC Agreement into shares of common stock	`ConversionOfLineOfCreditAgreementIntoCommonStock`	$718.33K	USD	Annual
Conversion of 8% Senior Convertible Notes into shares of common stock	`ConversionOfSeniorConvertibleNotesOfCommonStock`	$889.51K	USD	Annual
Stock dividend distributed due to full-ratchet anti-dilution adjustment	`StockDividendDistributedDueToFullratchetAntidilutionAdjustment`	-	USD	Annual
Fair value of warrants issued in the sale of our 2019 Senior Notes	`DebtIssuanceCostsAttributedToWarrantsIssuedInSaleOfSeniorNotes`	$197.40K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.73M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$510.48K	USD	Annual
Shares withheld to pay income tax on stock-based compensation	`SharesWithheldToPayIncomeTaxOnStockbasedCompensation`	$95.21K	USD	Annual
Shares withheld to pay income tax on stock-based compensation	`SharesWithheldToPayIncomeTaxOnStockbasedCompensation`	-	USD	Annual
Net loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net loss	`NetIncomeLoss`	$-14.41M	USD	Annual
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time
Balance	`StockholdersEquity`	$22.94M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.